memantine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
adamantane derivatives	1679	19982-08-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: memantine alzantin memantina memantine hydrochloride ebixa namenda maruxa memantine HCl nemdatine	AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent. Molecular weight: 179.31 Formula: C12H21N CLOGP: 3.03 LIPINSKI: 0 HAC: 1 HDO: 1 TPSA: 26.02 ALOGS: -3.60 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

memantine
alzantin
memantina
memantine hydrochloride
ebixa
namenda
maruxa
memantine HCl
nemdatine

AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent.

Molecular weight: 179.31
Formula: C12H21N
CLOGP: 3.03
LIPINSKI: 0
HAC: 1
HDO: 1
TPSA: 26.02
ALOGS: -3.60
ROTB: 0

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.32 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Hosey CM, Chan R, Benet LZ
EoM (Fraction excreted unchanged in urine)	48 %	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility)	30 mg/mL	Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma)	0.53 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

Date	Agency	Company	Orphan
May 15, 2002	EMA	H. Lundbeck A/S
Oct. 16, 2003	FDA	FOREST LABS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Fall	308.35	14.81	495	20077	391839	63076611
Agitation	230.21	14.81	175	20397	59582	63408868
Confusional state	214.15	14.81	319	20253	236061	63232389
Aggression	167.93	14.81	101	20471	23397	63445053
Hallucination	160.99	14.81	137	20435	54680	63413770
Dementia	145.31	14.81	85	20487	18709	63449741
Abnormal behaviour	145.14	14.81	89	20483	21337	63447113
Body tinea	144.85	14.81	44	20528	1841	63466609
Somnolence	137.64	14.81	224	20348	178461	63289989
Inhibitory drug interaction	123.14	14.81	43	20529	2806	63465644
Infection susceptibility increased	121.56	14.81	45	20527	3476	63464974
Delirium	108.54	14.81	106	20466	50435	63418015
Myoclonus	105.14	14.81	65	20507	15803	63452647
Glucose tolerance impaired	97.49	14.81	46	20526	6531	63461919
Bradycardia	90.44	14.81	115	20457	73112	63395338
Seizure	84.55	14.81	153	20419	132481	63335969
Psychomotor hyperactivity	81.81	14.81	48	20524	10615	63457835
Purpura	76.34	14.81	47	20525	11338	63457112
Poor quality sleep	71.47	14.81	56	20516	19879	63448571
Syncope	70.50	14.81	132	20440	117253	63351197
Rheumatoid arthritis	66.30	14.81	4	20568	253815	63214635
Impaired quality of life	65.79	14.81	46	20526	13737	63454713
Hallucination, visual	64.45	14.81	52	20520	19246	63449204
Loss of consciousness	63.79	14.81	127	20445	117994	63350456
Urinary tract infection	61.52	14.81	207	20365	264477	63203973
Bone density decreased	61.10	14.81	45	20527	14567	63453883
Joint swelling	60.09	14.81	16	20556	327650	63140800
Encephalopathy	59.69	14.81	68	20504	38552	63429898
Disorientation	58.51	14.81	68	20504	39384	63429066
Arthralgia	57.55	14.81	60	20512	569650	62898800
Delusion	57.11	14.81	40	20532	11977	63456473
Sialoadenitis	56.36	14.81	21	20551	1651	63466799
Aphasia	55.97	14.81	61	20511	32939	63435511
Maternal exposure during pregnancy	55.89	14.81	4	20568	220058	63248392
Cellulitis	55.34	14.81	97	20475	81861	63386589
Hyperlipidaemia	53.52	14.81	47	20525	19524	63448926
Pain	52.05	14.81	101	20471	740527	62727923
Impaired work ability	51.91	14.81	44	20528	17431	63451019
Swelling	51.33	14.81	13	20559	275365	63193085
Infusion related reaction	51.06	14.81	9	20563	245512	63222938
Dyskinesia	50.56	14.81	57	20515	31945	63436505
Arthropathy	50.17	14.81	8	20564	234784	63233666
Dysphagia	48.72	14.81	96	20476	88489	63379961
Drug hypersensitivity	48.51	14.81	20	20552	310667	63157783
Speech disorder	47.30	14.81	62	20510	40567	63427883
Death	46.79	14.81	242	20330	374139	63094311
Amyloid related imaging abnormality-oedema/effusion	46.46	14.81	11	20561	173	63468277
Alopecia	46.19	14.81	26	20546	337510	63130940
Hyponatraemia	44.09	14.81	106	20466	111794	63356656
Gait disturbance	43.16	14.81	144	20428	183034	63285416
Product administration interrupted	43.07	14.81	24	20548	4812	63463638
Drug interaction	42.83	14.81	167	20405	228964	63239486
Systemic lupus erythematosus	42.70	14.81	8	20564	208910	63259540
Chorea	42.61	14.81	17	20555	1607	63466843
Depressed level of consciousness	42.58	14.81	74	20498	62004	63406446
Orthostatic hypotension	41.81	14.81	55	20517	36105	63432345
Cognitive disorder	41.54	14.81	69	20503	55746	63412704
Mental status changes	40.88	14.81	57	20515	39542	63428908
Skin disorder	40.67	14.81	49	20523	29458	63438992
Oral herpes	40.44	14.81	46	20526	26028	63442422
Hypernatraemia	40.10	14.81	27	20545	7582	63460868
Myocardial oedema	39.88	14.81	10	20562	202	63468248
Sinusitis	39.79	14.81	12	20560	226641	63241809
Urinary retention	39.63	14.81	49	20523	30252	63438198
Tremor	39.55	14.81	113	20459	132126	63336324
Electrocardiogram PR prolongation	39.43	14.81	13	20559	711	63467739
Drug intolerance	39.12	14.81	26	20546	308635	63159815
Dementia Alzheimer's type	38.26	14.81	14	20558	1046	63467404
Lack of spontaneous speech	36.98	14.81	9	20563	160	63468290
Intestinal pseudo-obstruction	36.49	14.81	13	20559	899	63467551
Lethargy	36.13	14.81	65	20507	55942	63412508
Product adhesion issue	35.56	14.81	21	20551	4698	63463752
Altered state of consciousness	34.94	14.81	42	20530	25188	63443262
Electrocardiogram QT prolonged	34.53	14.81	66	20506	59464	63408986
Abdominal discomfort	34.39	14.81	32	20540	320853	63147597
Immune thrombocytopenia	34.30	14.81	28	20544	10528	63457922
Cerebral atrophy	34.18	14.81	21	20551	5045	63463405
Exposure during pregnancy	33.90	14.81	5	20567	155542	63312908
Incoherent	33.72	14.81	20	20552	4510	63463940
Anxiety disorder	33.10	14.81	19	20553	4031	63464419
Sedation	33.02	14.81	51	20521	38758	63429692
Pneumonia aspiration	31.67	14.81	47	20525	34493	63433957
Accidental overdose	30.97	14.81	38	20534	23271	63445179
Contraindicated product administered	30.86	14.81	16	20556	217632	63250818
Posture abnormal	30.58	14.81	15	20557	2317	63466133
Dehydration	30.48	14.81	124	20448	173230	63295220
Balance disorder	30.10	14.81	77	20495	84345	63384105
Failure to thrive	29.71	14.81	22	20550	7176	63461274
Pulmonary embolism	29.50	14.81	94	20478	116590	63351860
Hypophagia	29.33	14.81	43	20529	31216	63437234
Hypersensitivity	29.27	14.81	31	20541	292654	63175796
Treatment failure	29.17	14.81	14	20558	199029	63269421
Behaviour disorder	28.83	14.81	16	20556	3183	63465267
Immobile	28.74	14.81	20	20552	5923	63462527
Dyspnoea	28.58	14.81	114	20458	661199	62807251
Cerebral haemorrhage	28.44	14.81	42	20530	30687	63437763
Hip fracture	28.31	14.81	41	20531	29433	63439017
Cataract	28.00	14.81	59	20513	56994	63411456
Belligerence	27.35	14.81	7	20565	154	63468296
Metastatic neoplasm	26.94	14.81	17	20555	4278	63464172
Disturbance in attention	26.80	14.81	46	20526	38143	63430307
Akinesia	26.27	14.81	12	20560	1581	63466869
Emotional poverty	25.96	14.81	8	20564	351	63468099
Febrile neutropenia	25.36	14.81	4	20568	118445	63350005
Nasopharyngitis	25.34	14.81	27	20545	254230	63214220
Decreased appetite	25.13	14.81	153	20419	250899	63217551
Lower respiratory tract infection	25.11	14.81	6	20566	132301	63336149
Akathisia	25.08	14.81	22	20550	9124	63459326
Hypersomnia	24.91	14.81	30	20542	18025	63450425
Therapeutic product effect decreased	24.82	14.81	16	20556	193171	63275279
Rash	24.65	14.81	96	20476	560775	62907675
Asthenia	24.61	14.81	210	20362	383394	63085056
Discomfort	24.18	14.81	12	20560	167362	63301088
Restlessness	24.07	14.81	38	20534	29415	63439035
Pyrexia	23.69	14.81	76	20496	470402	62998048
Memory impairment	23.67	14.81	81	20491	104177	63364273
Inappropriate antidiuretic hormone secretion	23.50	14.81	27	20545	15435	63453015
Head injury	23.30	14.81	36	20536	27360	63441090
Stomatitis	23.18	14.81	8	20564	138717	63329733
Dizziness	22.84	14.81	226	20346	429699	63038751
Pain in extremity	22.49	14.81	46	20526	331440	63137010
Hepatic enzyme increased	21.87	14.81	20	20552	202308	63266142
Eye haematoma	21.86	14.81	5	20567	67	63468383
Diet refusal	21.68	14.81	8	20564	612	63467838
Parkinsonism	20.73	14.81	21	20551	10418	63458032
Irritability	20.71	14.81	37	20535	31657	63436793
Gait inability	20.66	14.81	50	20522	52909	63415541
Abdominal pain	20.52	14.81	40	20532	293416	63175034
Blood creatine phosphokinase increased	20.50	14.81	36	20536	30394	63438056
Drug-device interaction	20.43	14.81	5	20567	91	63468359
Device pacing issue	20.38	14.81	5	20567	92	63468358
Crying	20.31	14.81	31	20541	23312	63445138
Dermatitis atopic	20.12	14.81	20	20552	9704	63458746
Metastases to central nervous system	20.11	14.81	23	20549	13082	63455368
Psoriatic arthropathy	19.80	14.81	3	20569	91517	63376933
Wrong patient received product	19.78	14.81	11	20561	2196	63466254
Stupor	19.77	14.81	14	20558	4261	63464189
Schizophrenia	19.73	14.81	20	20552	9932	63458518
Parkinson's disease	19.53	14.81	9	20563	1210	63467240
Epilepsy	19.52	14.81	33	20539	27032	63441418
Anger	19.35	14.81	22	20550	12434	63456016
Floppy iris syndrome	19.24	14.81	5	20567	117	63468333
Wound	19.03	14.81	15	20557	163248	63305202
Vitamin D deficiency	19.03	14.81	23	20549	13869	63454581
Therapeutic drug monitoring analysis not performed	18.64	14.81	9	20563	1343	63467107
Aptyalism	18.63	14.81	7	20565	563	63467887
Subdural haematoma	18.46	14.81	23	20549	14305	63454145
Angina pectoris	18.24	14.81	34	20538	30044	63438406
Extrapyramidal disorder	18.20	14.81	22	20550	13262	63455188
Infection	18.04	14.81	29	20543	229144	63239306
Anaemia neonatal	17.98	14.81	6	20566	341	63468109
Headache	17.90	14.81	126	20446	633115	62835335
Retinopathy of prematurity	17.78	14.81	6	20566	353	63468097
Eating disorder	17.61	14.81	26	20546	18990	63449460
Diabetic hyperosmolar coma	17.60	14.81	6	20566	364	63468086
Muscle rigidity	17.34	14.81	20	20552	11480	63456970
Incontinence	17.15	14.81	20	20552	11612	63456838
Oroantral fistula	16.82	14.81	5	20567	194	63468256
Non-24-hour sleep-wake disorder	16.71	14.81	3	20569	10	63468440
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits	16.60	14.81	4	20568	68	63468382
Pruritus	16.41	14.81	61	20511	361392	63107058
Psoriasis	16.38	14.81	4	20568	86953	63381497
Granulocytopenia	16.27	14.81	14	20558	5658	63462792
Apathy	16.22	14.81	17	20555	8777	63459673
Insomnia	16.03	14.81	122	20450	215130	63253320
Moaning	15.96	14.81	7	20565	839	63467611
Application site rash	15.95	14.81	10	20562	2488	63465962
Neutropenia	15.90	14.81	20	20552	174985	63293465
Arthritis	15.72	14.81	9	20563	115912	63352538
Pleurothotonus	15.70	14.81	8	20564	1341	63467109
Personality change	15.66	14.81	15	20557	6958	63461492
Nausea	15.52	14.81	190	20382	854281	62614169
Unresponsive to stimuli	15.47	14.81	34	20538	33782	63434668
Decubitus ulcer	15.37	14.81	18	20554	10502	63457948
Gastrointestinal disorder	15.37	14.81	12	20560	131227	63337223
Visual impairment	15.29	14.81	61	20511	84385	63384065
Medication error	14.95	14.81	44	20528	52240	63416210

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hallucination	277.44	15.40	204	14408	51294	34891025
Confusional state	235.72	15.40	295	14317	143865	34798454
Fall	224.83	15.40	344	14268	202541	34739778
Dementia	141.91	15.40	82	14530	13666	34928653
Aggression	124.44	15.40	114	14498	38850	34903469
Abnormal behaviour	116.72	15.40	91	14521	24878	34917441
Somnolence	104.15	15.40	175	14437	110941	34831378
Agitation	91.08	15.40	116	14496	57283	34885036
Gait disturbance	83.61	15.40	137	14475	85003	34857316
Delusion	72.28	15.40	52	14560	12583	34929736
Pleurothotonus	69.26	15.40	24	14588	1181	34941138
Death	68.24	15.40	337	14275	397712	34544607
Orthostatic hypotension	67.85	15.40	68	14544	25851	34916468
Bradycardia	65.59	15.40	115	14497	75303	34867016
Delirium	65.21	15.40	86	14526	43905	34898414
Amyloid related imaging abnormality-oedema/effusion	63.93	15.40	16	14596	245	34942074
Sopor	58.35	15.40	45	14567	12091	34930228
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits	53.99	15.40	13	14599	168	34942151
Memory impairment	49.81	15.40	75	14537	43243	34899076
Product administration interrupted	49.51	15.40	21	14591	1794	34940525
Eosinophilic pleural effusion	48.73	15.40	13	14599	259	34942060
Mental status changes	45.30	15.40	67	14545	38016	34904303
Pneumonia aspiration	43.21	15.40	69	14543	41834	34900485
Product adhesion issue	41.95	15.40	18	14594	1582	34940737
Prescribed underdose	40.51	15.40	32	14580	8901	34933418
Condition aggravated	39.56	15.40	172	14440	192024	34750295
Febrile neutropenia	37.76	15.40	6	14606	136843	34805476
Spur cell anaemia	37.39	15.40	8	14604	58	34942261
Syncope	36.47	15.40	102	14510	91349	34850970
Balance disorder	35.31	15.40	62	14550	40592	34901727
Gait inability	34.54	15.40	43	14569	20715	34921604
Asthenia	32.55	15.40	194	14418	245057	34697262
Subdural haematoma	31.91	15.40	41	14571	20380	34921939
Foaming at mouth	30.96	15.40	12	14600	812	34941507
Loss of consciousness	30.81	15.40	90	14522	82577	34859742
Bradyarrhythmia	30.69	15.40	16	14596	2175	34940144
Psychomotor hyperactivity	30.37	15.40	28	14584	9594	34932725
Hallucination, visual	29.83	15.40	37	14575	17754	34924565
Dementia with Lewy bodies	28.97	15.40	11	14601	704	34941615
Dysphagia	28.30	15.40	73	14539	62308	34880011
Depressed level of consciousness	28.13	15.40	58	14554	42783	34899536
Urinary tract infection	28.01	15.40	88	14524	83993	34858326
Cognitive disorder	27.87	15.40	46	14566	28647	34913672
Hypersomnia	27.86	15.40	30	14582	12377	34929942
Hyporesponsive to stimuli	27.52	15.40	12	14600	1096	34941223
Ataxia	26.82	15.40	31	14581	13822	34928497
Speech disorder	26.06	15.40	42	14570	25644	34916675
Dyskinesia	26.02	15.40	39	14573	22374	34919945
Mixed dementia	25.97	15.40	8	14604	270	34942049
Tremor	25.30	15.40	84	14528	82503	34859816
Sedation	25.03	15.40	37	14575	20969	34921350
Inappropriate antidiuretic hormone secretion	23.79	15.40	28	14584	12725	34929594
Urinary incontinence	23.58	15.40	34	14578	18840	34923479
Hypophagia	22.64	15.40	38	14574	23984	34918335
Medication error	22.20	15.40	39	14573	25526	34916793
Myoclonus	22.12	15.40	29	14583	14696	34927623
Nonspecific reaction	21.78	15.40	11	14601	1400	34940919
Drug hypersensitivity	21.17	15.40	4	14608	80525	34861794
Disorientation	20.69	15.40	44	14568	33144	34909175
Conduction disorder	20.21	15.40	12	14600	2098	34940221
Restlessness	19.75	15.40	37	14575	25445	34916874
Product dose omission issue	19.36	15.40	100	14512	119611	34822708
Sinus bradycardia	18.66	15.40	25	14587	12938	34929381
Seizure	18.66	15.40	90	14522	104767	34837552
Decreased appetite	18.53	15.40	126	14486	166266	34776053
Neutropenia	18.51	15.40	23	14589	156755	34785564
Hypernatraemia	18.14	15.40	20	14592	8470	34933849
Disturbance in attention	18.06	15.40	36	14576	25909	34916410
Accidental overdose	17.85	15.40	31	14581	20109	34922210
Therapeutic response unexpected	17.50	15.40	21	14591	9736	34932583
Illusion	17.48	15.40	8	14604	819	34941500
Parkinsonism	17.09	15.40	19	14593	8119	34934200
Paranoia	16.95	15.40	23	14589	12045	34930274
Dysstasia	16.76	15.40	23	14589	12172	34930147
Application site erythema	16.62	15.40	11	14601	2325	34939994
Abnormal dreams	16.45	15.40	18	14594	7560	34934759
Decreased activity	16.30	15.40	14	14598	4373	34937946
Electrocardiogram QT prolonged	15.64	15.40	45	14567	40907	34901412

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Fall	437.32	13.81	696	28324	486933	79228435
Confusional state	355.92	13.81	504	28516	317493	79397875
Hallucination	300.18	13.81	249	28771	85496	79629872
Aggression	230.05	13.81	172	28848	50786	79664582
Agitation	226.12	13.81	227	28793	99488	79615880
Dementia	195.19	13.81	118	28902	24541	79690827
Somnolence	184.80	13.81	320	28700	238661	79476707
Abnormal behaviour	171.22	13.81	126	28894	36295	79679073
Bradycardia	138.20	13.81	206	28814	135351	79580017
Body tinea	136.36	13.81	43	28977	1811	79713557
Death	128.04	13.81	474	28546	566040	79149328
Myoclonus	123.97	13.81	93	28927	27567	79687801
Delirium	120.12	13.81	151	28869	84476	79630892
Infection susceptibility increased	110.55	13.81	44	28976	3677	79711691
Delusion	110.54	13.81	77	28943	20346	79695022
Psychomotor hyperactivity	99.41	13.81	67	28953	16782	79698586
Gait disturbance	96.55	13.81	225	28795	207281	79508087
Inhibitory drug interaction	96.36	13.81	42	28978	4411	79710957
Amyloid related imaging abnormality-oedema/effusion	92.10	13.81	23	28997	404	79714964
Orthostatic hypotension	87.40	13.81	105	28915	56059	79659309
Pleurothotonus	86.23	13.81	33	28987	2483	79712885
Loss of consciousness	84.64	13.81	188	28832	167755	79547613
Product administration interrupted	81.85	13.81	36	28984	3863	79711505
Glucose tolerance impaired	80.72	13.81	45	28975	8039	79707329
Syncope	78.49	13.81	190	28830	179259	79536109
Hallucination, visual	76.83	13.81	76	28944	32653	79682715
Pneumonia aspiration	74.31	13.81	106	28914	66861	79648507
Mental status changes	71.40	13.81	104	28916	66855	79648513
Seizure	70.17	13.81	188	28832	188646	79526722
Arthralgia	68.99	13.81	64	28956	571739	79143629
Poor quality sleep	61.35	13.81	57	28963	22665	79692703
Drug hypersensitivity	60.37	13.81	17	29003	298899	79416469
Rheumatoid arthritis	60.18	13.81	4	29016	208466	79506902
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits	58.44	13.81	14	29006	205	79715163
Bone density decreased	57.85	13.81	44	28976	13303	79702065
Disorientation	57.70	13.81	91	28929	62685	79652683
Speech disorder	57.22	13.81	84	28936	54361	79661007
Joint swelling	57.22	13.81	17	29003	288629	79426739
Depressed level of consciousness	56.52	13.81	115	28905	96537	79618831
Dyskinesia	55.86	13.81	75	28945	44698	79670670
Impaired quality of life	54.93	13.81	44	28976	14342	79701026
Asthenia	54.40	13.81	345	28675	511344	79204024
Tremor	54.02	13.81	160	28860	169923	79545445
Sialoadenitis	53.72	13.81	22	28998	1979	79713389
Urinary tract infection	53.04	13.81	219	28801	274293	79441075
Febrile neutropenia	52.87	13.81	10	29010	230989	79484379
Purpura	52.75	13.81	49	28971	19478	79695890
Eosinophilic pleural effusion	52.37	13.81	14	29006	325	79715043
Dysphagia	51.96	13.81	128	28892	122008	79593360
Cognitive disorder	51.76	13.81	92	28928	69834	79645534
Infusion related reaction	50.54	13.81	11	29009	230226	79485142
Inappropriate antidiuretic hormone secretion	49.02	13.81	54	28966	26259	79689109
Sopor	48.56	13.81	60	28960	32950	79682418
Electrocardiogram QT prolonged	47.55	13.81	103	28917	90283	79625085
Failure to thrive	46.88	13.81	37	28983	11807	79703561
Balance disorder	46.79	13.81	108	28912	98749	79616619
Hypophagia	44.81	13.81	68	28952	45299	79670069
Aphasia	44.69	13.81	69	28951	46663	79668705
Sedation	43.29	13.81	72	28948	51823	79663545
Disturbance in attention	43.07	13.81	71	28949	50730	79664638
Hyperlipidaemia	42.58	13.81	50	28970	26043	79689325
Arthropathy	41.97	13.81	7	29013	177104	79538264
Encephalopathy	41.55	13.81	82	28938	67315	79648053
Altered state of consciousness	40.92	13.81	64	28956	43758	79671610
Swelling	40.74	13.81	14	29006	216697	79498671
Hypersomnia	40.64	13.81	46	28974	23040	79692328
Posture abnormal	39.91	13.81	22	28998	3844	79711524
Dementia with Lewy bodies	39.75	13.81	14	29006	832	79714536
Subdural haematoma	39.73	13.81	53	28967	31381	79683987
Impaired work ability	39.48	13.81	42	28978	19639	79695729
Accidental overdose	37.23	13.81	58	28962	39523	79675845
Incoherent	37.01	13.81	27	28993	7665	79707703
Gait inability	36.70	13.81	72	28948	58845	79656523
Pain	36.23	13.81	133	28887	703669	79011699
Maternal exposure during pregnancy	35.65	13.81	4	29016	136534	79578834
Skin disorder	35.12	13.81	52	28968	33891	79681477
Hip fracture	34.56	13.81	49	28971	30712	79684656
Electrocardiogram PR prolongation	34.47	13.81	15	29005	1568	79713800
Memory impairment	34.40	13.81	104	28916	111630	79603738
Spur cell anaemia	33.66	13.81	8	29012	113	79715255
Drug interaction	33.53	13.81	262	28758	414921	79300447
Lack of spontaneous speech	33.03	13.81	9	29011	225	79715143
Hypernatraemia	32.88	13.81	33	28987	14418	79700950
Medication error	32.48	13.81	75	28945	68567	79646801
Lethargy	32.26	13.81	83	28937	81209	79634159
Decreased appetite	32.15	13.81	224	28796	342194	79373174
Sinusitis	31.32	13.81	16	29004	195485	79519883
Oral herpes	31.24	13.81	44	28976	27410	79687958
Dehydration	31.20	13.81	175	28845	248012	79467356
Bradyarrhythmia	30.64	13.81	19	29001	4127	79711241
Cerebral haemorrhage	30.64	13.81	66	28954	57607	79657761
Restlessness	30.40	13.81	58	28962	46434	79668934
Abdominal pain	30.29	13.81	60	28960	389509	79325859
Rash	29.93	13.81	109	28911	578249	79137119
Ataxia	29.79	13.81	41	28979	24998	79690370
Sinus bradycardia	29.53	13.81	41	28979	25206	79690162
Dyspnoea	29.50	13.81	187	28833	856838	78858530
Cerebral atrophy	29.35	13.81	24	28996	8051	79707317
Hyponatraemia	28.32	13.81	134	28886	177714	79537654
Neutropenia	28.26	13.81	38	28982	287672	79427696
Systemic lupus erythematosus	28.23	13.81	5	29015	121144	79594224
Contraindicated product administered	28.21	13.81	11	29009	157527	79557841
Neuroleptic malignant syndrome	28.20	13.81	42	28978	27517	79687851
Behaviour disorder	27.77	13.81	21	28999	6292	79709076
Head injury	27.43	13.81	49	28971	37320	79678048
Parkinsonism	27.43	13.81	32	28988	16552	79698816
Drug intolerance	26.85	13.81	34	28986	264085	79451283
Mixed dementia	26.71	13.81	8	29012	283	79715085
Stomatitis	26.69	13.81	10	29010	146747	79568621
Nasopharyngitis	26.52	13.81	32	28988	253849	79461519
Foaming at mouth	25.86	13.81	13	29007	1884	79713484
Urinary retention	25.83	13.81	61	28959	56569	79658799
Urinary incontinence	25.48	13.81	50	28970	40859	79674509
Hypersensitivity	25.39	13.81	35	28985	262204	79453164
Generalised tonic-clonic seizure	25.36	13.81	52	28968	43858	79671510
Mania	24.96	13.81	32	28988	18228	79697140
Crying	24.85	13.81	36	28984	23007	79692361
Prescribed underdose	24.68	13.81	41	28979	29473	79685895
Hyporesponsive to stimuli	24.68	13.81	13	29007	2075	79713293
Incontinence	24.55	13.81	28	28992	14136	79701232
International normalised ratio increased	24.35	13.81	77	28943	84644	79630724
Alopecia	24.34	13.81	29	28991	231326	79484042
Product adhesion issue	24.16	13.81	14	29006	2690	79712678
Pruritus	24.13	13.81	69	28951	394579	79320789
Akinesia	24.03	13.81	15	29005	3297	79712071
Dizziness	23.68	13.81	294	28726	526147	79189221
Anger	23.34	13.81	30	28990	17132	79698236
Irritability	22.91	13.81	48	28972	41096	79674272
Therapeutic product effect decreased	22.62	13.81	16	29004	163847	79551521
Cataract	22.18	13.81	61	28959	62059	79653309
Intestinal pseudo-obstruction	21.97	13.81	13	29007	2596	79712772
Exposure during pregnancy	21.84	13.81	5	29015	101127	79614241
Condition aggravated	21.73	13.81	278	28742	500846	79214522
Cerebral infarction	21.71	13.81	50	28970	45626	79669742
Pain in extremity	21.37	13.81	65	28955	364473	79350895
Muscle rigidity	21.35	13.81	31	28989	19851	79695517
Emotional poverty	21.28	13.81	9	29011	878	79714490
Akathisia	20.96	13.81	25	28995	13234	79702134
Arthritis	20.60	13.81	8	29012	114872	79600496
Paranoia	20.43	13.81	30	28990	19402	79695966
Eating disorder	20.40	13.81	31	28989	20666	79694702
Pyrexia	20.39	13.81	154	28866	678555	79036813
Chorea	20.24	13.81	12	29008	2405	79712963
Lower respiratory tract infection	20.07	13.81	11	29009	129209	79586159
Immobile	19.81	13.81	18	29002	6955	79708413
Headache	19.80	13.81	148	28872	653624	79061744
Extrapyramidal disorder	19.63	13.81	32	28988	22647	79692721
Intentional product use issue	19.52	13.81	16	29004	152096	79563272
Immune thrombocytopenia	19.47	13.81	28	28992	17777	79697591
Haemorrhagic stroke	19.42	13.81	22	28998	11024	79704344
Aptyalism	19.15	13.81	8	29012	757	79714611
Infection	18.97	13.81	37	28983	241675	79473693
Tardive dyskinesia	18.49	13.81	21	28999	10550	79704818
Hepatic enzyme increased	18.04	13.81	24	28996	182586	79532782
Discomfort	17.68	13.81	12	29008	125605	79589763
Asthma	17.60	13.81	14	29006	135081	79580287
Epilepsy	17.54	13.81	43	28977	40817	79674551
Dysstasia	17.39	13.81	34	28986	27712	79687656
Freezing phenomenon	17.34	13.81	10	29010	1904	79713464
Unresponsive to stimuli	17.23	13.81	52	28968	55736	79659632
Cellulitis	17.22	13.81	82	28938	108978	79606390
Suicidal ideation	17.21	13.81	64	28956	76276	79639092
Eye haematoma	17.08	13.81	5	29015	163	79715205
Marasmus	16.88	13.81	8	29012	1020	79714348
Metastases to central nervous system	16.81	13.81	25	28995	16350	79699018
Electrocardiogram J wave	16.61	13.81	4	29016	60	79715308
Cerebrovascular accident	16.60	13.81	105	28915	155187	79560181
Apathy	16.58	13.81	22	28998	12955	79702413
Conduction disorder	16.57	13.81	12	29008	3367	79712001
Decreased activity	16.46	13.81	18	29002	8676	79706692
Nasal congestion	16.11	13.81	4	29016	76548	79638820
Helicobacter infection	15.97	13.81	3	29017	69701	79645667
Abdominal discomfort	15.93	13.81	43	28977	250684	79464684
Cough	15.89	13.81	74	28946	366715	79348653
Impaired healing	15.89	13.81	6	29014	87649	79627719
Serotonin syndrome	15.86	13.81	44	28976	44983	79670385
Hyperglycaemic hyperosmolar nonketotic syndrome	15.63	13.81	10	29010	2293	79713075
Granulocytopenia	15.57	13.81	20	29000	11411	79703957
Illusion	15.52	13.81	9	29011	1732	79713636
Fluid intake reduced	15.50	13.81	15	29005	6273	79709095
Neuropsychological test abnormal	15.39	13.81	3	29017	15	79715353
Atrioventricular block	15.23	13.81	22	28998	14019	79701349
Drowning	15.18	13.81	7	29013	838	79714530
Insomnia	15.18	13.81	146	28874	245024	79470344
Drug-device interaction	15.17	13.81	4	29016	88	79715280
Completed suicide	14.98	13.81	43	28977	245724	79469644
Diet refusal	14.98	13.81	7	29013	864	79714504
Urticaria	14.83	13.81	28	28992	185173	79530195
Decubitus ulcer	14.76	13.81	23	28997	15664	79699704
Normal pressure hydrocephalus	14.68	13.81	6	29014	537	79714831
Therapeutic drug monitoring analysis not performed	14.63	13.81	9	29011	1927	79713441
Neuropathy peripheral	14.55	13.81	18	29002	141287	79574081
Neuropsychiatric symptoms	14.46	13.81	8	29012	1407	79713961
Contusion	14.33	13.81	98	28922	148678	79566690
Lower gastrointestinal haemorrhage	14.29	13.81	23	28997	16102	79699266
Executive dysfunction	14.22	13.81	5	29015	296	79715072
Belligerence	14.01	13.81	5	29015	309	79715059
Dementia Alzheimer's type	13.94	13.81	7	29013	1012	79714356
Application site rash	13.84	13.81	9	29011	2123	79713245

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06DA52	NERVOUS SYSTEM PSYCHOANALEPTICS ANTI-DEMENTIA DRUGS Anticholinesterases
ATC	N06DA53	NERVOUS SYSTEM PSYCHOANALEPTICS ANTI-DEMENTIA DRUGS Anticholinesterases
ATC	N06DX01	NERVOUS SYSTEM PSYCHOANALEPTICS ANTI-DEMENTIA DRUGS Other anti-dementia drugs
FDA MoA	N0000020015	NMDA Receptor Antagonists
MeSH PA	D018726	Anti-Dyskinesia Agents
MeSH PA	D000978	Antiparkinson Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018691	Excitatory Amino Acid Antagonists
MeSH PA	D018377	Neurotransmitter Agents
FDA EPC	N0000175745	N-methyl-D-aspartate Receptor Antagonist
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:48407	antiparkinson agent
CHEBI has role	CHEBI:48560	dopaminergic agents
CHEBI has role	CHEBI:60643	N-methyl-D-aspartate receptor antagonists
CHEBI has role	CHEBI:63726	neuroprotective agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Moderate to Severe Alzheimer's Type Dementia	indication
Acute nephropathy	contraindication	58574008
Impaired renal function disorder	contraindication	197663003
Disease of liver	contraindication	235856003	DOID:409

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.37	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
10MG;14MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8173708	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8283379	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8338486	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8362085	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8580858	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8173708	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8283379	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8338486	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8362085	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8580858	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8173708	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8283379	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8338486	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8362085	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8580858	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8173708	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8283379	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8338486	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8362085	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8580858	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
14MG	NAMENDA XR	ABBVIE	N022525	June 21, 2010	RX	CAPSULE, EXTENDED RELEASE	ORAL	8039009	March 24, 2029	TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
21MG	NAMENDA XR	ABBVIE	N022525	June 21, 2010	RX	CAPSULE, EXTENDED RELEASE	ORAL	8039009	March 24, 2029	TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
28MG	NAMENDA XR	ABBVIE	N022525	June 21, 2010	RX	CAPSULE, EXTENDED RELEASE	ORAL	8039009	March 24, 2029	TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
7MG	NAMENDA XR	ABBVIE	N022525	June 21, 2010	RX	CAPSULE, EXTENDED RELEASE	ORAL	8039009	March 24, 2029	TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8039009	March 24, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8039009	March 24, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8039009	March 24, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8039009	March 24, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8058291	Dec. 5, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8058291	Dec. 5, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8058291	Dec. 5, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8058291	Dec. 5, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Glutamate receptor ionotropic, NMDA 3A	Ion channel	Q8TCU5	NMD3A_HUMAN	NEGATIVE ALLOSTERIC MODULATOR			WOMBAT-PK	CHEMBL
Glutamate receptor ionotropic, NMDA 1	Ion channel	Q05586	NMDZ1_HUMAN	NEGATIVE ALLOSTERIC MODULATOR	IC50	5.02	CHEMBL	CHEMBL
Glutamate NMDA receptor; GRIN1/GRIN2B	Ion channel	Q05586 Q13224	NMDZ1_HUMAN NMDE2_HUMAN	NEGATIVE ALLOSTERIC MODULATOR	IC50	5.26	CHEMBL	CHEMBL
Glutamate NMDA receptor; GRIN1/GRIN2A	Ion channel	Q05586 Q12879	NMDZ1_HUMAN NMDE1_HUMAN	NEGATIVE ALLOSTERIC MODULATOR	IC50	9.02	CHEMBL	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.57	CHEMBL
Acetylcholinesterase	Enzyme	P22303	ACES_HUMAN		IC50	8.31	CHEMBL
5-hydroxytryptamine receptor 3A	Ion channel	P46098	5HT3A_HUMAN				WOMBAT-PK
Glutamate receptor ionotropic, NMDA 2C	Ion channel		NMDE3_RAT		Ki	6.15	CHEMBL

External reference:

ID	Source
4021409	VUID
N0000148824	NUI
D04905	KEGG_DRUG
41100-52-1	SECONDARY_CAS_RN
4021409	VANDF
C0025242	UMLSCUI
CHEBI:64312	CHEBI
377	PDB_CHEM_ID
CHEMBL1699	ChEMBL_ID
CHEMBL807	ChEMBL_ID
DB01043	DRUGBANK_ID
D008559	MESH_DESCRIPTOR_UI
4054	PUBCHEM_CID
3952	INN_ID
4253	IUPHAR_LIGAND_ID
W8O17SJF3T	UNII
236685	RXNORM
169783	MMSL
17635	MMSL
203022	MMSL
47628	MMSL
d04899	MMSL
006597	NDDF
006598	NDDF
406457005	SNOMEDCT_US
406458000	SNOMEDCT_US
426610008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Memantine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0850	SOLUTION	10 mg	ORAL	ANDA	32 sections
Memantine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0850	SOLUTION	10 mg	ORAL	ANDA	32 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1207	CAPSULE	7 mg	ORAL	NDA	31 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1207	CAPSULE	7 mg	ORAL	NDA	31 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1214	CAPSULE	14 mg	ORAL	NDA	31 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1214	CAPSULE	14 mg	ORAL	NDA	31 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1221	CAPSULE	21 mg	ORAL	NDA	31 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1221	CAPSULE	21 mg	ORAL	NDA	31 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1228	CAPSULE	28 mg	ORAL	NDA	31 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1228	CAPSULE	28 mg	ORAL	NDA	31 sections
Namenda	HUMAN PRESCRIPTION DRUG LABEL	1	0456-3205	TABLET	5 mg	ORAL	NDA	31 sections
Namenda	HUMAN PRESCRIPTION DRUG LABEL	1	0456-3205	TABLET	5 mg	ORAL	NDA	31 sections
Namenda	HUMAN PRESCRIPTION DRUG LABEL	1	0456-3210	TABLET	10 mg	ORAL	NDA	31 sections
Namenda	HUMAN PRESCRIPTION DRUG LABEL	1	0456-3210	TABLET	10 mg	ORAL	NDA	31 sections
NamendaXR	HUMAN PRESCRIPTION DRUG LABEL	1	0456-3407	CAPSULE, EXTENDED RELEASE	7 mg	ORAL	NDA	31 sections
NamendaXR	HUMAN PRESCRIPTION DRUG LABEL	1	0456-3407	CAPSULE, EXTENDED RELEASE	7 mg	ORAL	NDA	31 sections
NamendaXR	HUMAN PRESCRIPTION DRUG LABEL	1	0456-3414	CAPSULE, EXTENDED RELEASE	14 mg	ORAL	NDA	31 sections
NamendaXR	HUMAN PRESCRIPTION DRUG LABEL	1	0456-3414	CAPSULE, EXTENDED RELEASE	14 mg	ORAL	NDA	31 sections
NamendaXR	HUMAN PRESCRIPTION DRUG LABEL	1	0456-3421	CAPSULE, EXTENDED RELEASE	21 mg	ORAL	NDA	31 sections
NamendaXR	HUMAN PRESCRIPTION DRUG LABEL	1	0456-3421	CAPSULE, EXTENDED RELEASE	21 mg	ORAL	NDA	31 sections
NamendaXR	HUMAN PRESCRIPTION DRUG LABEL	1	0456-3428	CAPSULE, EXTENDED RELEASE	28 mg	ORAL	NDA	31 sections
NamendaXR	HUMAN PRESCRIPTION DRUG LABEL	1	0456-3428	CAPSULE, EXTENDED RELEASE	28 mg	ORAL	NDA	31 sections
Memantine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1221	TABLET	5 mg	ORAL	ANDA	27 sections
Memantine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1221	TABLET	5 mg	ORAL	ANDA	27 sections
Memantine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1222	TABLET	10 mg	ORAL	ANDA	27 sections
Memantine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1222	TABLET	10 mg	ORAL	ANDA	27 sections
Memantine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1943	SOLUTION	2 mg	ORAL	ANDA	28 sections
Memantine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1943	SOLUTION	2 mg	ORAL	ANDA	28 sections
Memantine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1943	SOLUTION	2 mg	ORAL	ANDA	28 sections
memantine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3870	TABLET	5 mg	ORAL	NDA	29 sections